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1. Introduction 
Lesions of focal segmental glomerulosclerosis (FSGS) are a pathological hallmark of 
progressive glomerular injury. Glomerulosclerosis frequently complicates most renal 
diseases, and is characterized by the collapse of the glomerular tuft with the accumulation 
of mesangial matrix. Transforming growth factor-ß (TGF-ß) is a key regulator of 
extracellular matrix (ECM) protein synthesis in renal cells. TGF-ß is secreted as latent 
complexes, which are stored in the ECM to provide stability to the active molecule and a 
readily activable source of it (Lawrence 2001). Overexpression of active TGF-ß1 in 
transgenic mice causes mesangial expansion and thickened capillary loops in the 
glomeruli (Kopp et al. 1996), while monoclonal antibody to TGF-ß reduces the 
glomerulosclerosis in experimental proliferative glomerulonephritis (GN) (Yu et al. 2004) 
and diabetic nephropathy (Benigni et al. 2003; Ziyadeh et al. 2000). 
Cultured mesangial cells secrete TGF-ß and ECM proteins in response to various fibrogenic 
stimuli (Kim et al. 2001; Lee et al. 2004; Lee and Song 2009a; Ziyadeh et al. 1994, 1998). In 
chronic mesangial diseases, such as IgA nephropathy (IgAN) and diabetic nephropathy, 
TGF-ß1 mRNA expression by mesangial cells is increased, yet mesangial immunostaining 
for active TGF-ß1 is frequently negative (Kim et al. 2002; Stein-Oakley et al. 1997; Wahab et 
al. 2005). Only podocytes covering the sclerotic segments exhibit increased expression of 
TGF-ß1 protein (Kim et al. 2002; Wahab et al. 2005). These findings suggest that mesangial 
cells secrete latent TGF-ß in chronic mesangial disease, which may be localized to the 
podocyte surface to be activated (Lee and Song 2009b). 
Podocytes are the target of injury in most glomerular diseases. Expression of TGF-ß mRNA 
and/or protein by podocytes is increased in progressive podocyte diseases, such as primary 
FSGS, membranous nephropathy, Alport syndrome and Denys-Drash syndrome (Kim et al. 
2003; Kim et al. 1999; Patek et al. 2003; Sayers et al. 1999; Shankland et al. 1996). In addition, 
mesangial matrix is frequently increased in association with glomerulosclerosis (Gregory et 
al. 1996; Lee and Koh 1993; Lee and Lim 1995; Kim et al. 1995; Patek et al. 2003). Thus, TGF-
ß, that is expressed and/or activated by podocytes, may contribute to mesangial matrix 
oversynthesis in both chronic mesangial disease and podocyte disease (Lee 2011). 
This review will discuss the recent findings on the mechanisms and consequences of latent 
TGF-ß activation and TGF-ß-induced mesangial matrix accumulation in chronic progressive 
glomerular disease.  
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2. Structure of mesangial cells 
Glomerular mesangial cells together with their surrounding matrix constitute the 
mesangium, a structure that is separated from the capillary lumen by the endothelium. The 
mesangial cells are surrounded by mesangial matrix, that is similar but not identical to the 
peripheral glomerular basement membrane (GBM). The mesangial matrix contains type IV 
collagen, sulfated glycosaminoglycans, fibronectin and laminin. The mesangial cells are 
often compared with vascular smooth muscle cells, and are able to proliferate and produce 
excessive matrix proteins when stimulated. 
3. Chronic progressive glomerular diseases with TGF-ß overexpression in 
podocytes 
3.1 IgAN 
The diagnosis of IgAN is based on the demonstration of predominant or codominant IgA 
deposition in the mesangium. The glomerular histopathology mainly represents the 
mesangial lesions showing cell proliferation and/or matrix expansion.  In addition, focal 
abnormalities of the GBM are sometimes present, with reticulation, thinning and thickening, 
as well as subepithelial deposits (Lee et al. 1987, 1989).  Up to 30% of patients with IgAN 
eventually progress to end-stage renal disease (ESRD) after a follow-up of 25 years (Ibels 
and Györy 1994). The more severe glomerular lesions, which have higher percentage of 
glomerulosclerosis and crescents, are significantly related to progressive IgAN (El Karoui et 
al. 2011; Lee et al. 2005). Other glomerular lesions, such as mesangial hyperplasia and 
endocapillary lesions, also contribute to worse prognosis (Working Group of the 
International IgA Nephropathy Network 2010).  
The intensity of immunostaining for platelet-derived growth factor, type IV collagen, 
laminin, and fibronectin is increased in the mesangium in renal biopsies with IgAN (Kim 
et al. 2002). In the early stage of IgAN with mesangial cell proliferation, some mesangial 
cells show immunoreactivity for TGF-ß1 (Stein-Oakley et al. 1997). Mesangial 
immunostaining for active TGF-ß1, however, is very weak or almost negligible in most 
human IgAN, despite increased mesangial TGF-ß1 mRNA levels. Instead, hyperplastic 
podocytes covering the sclerotic segments exhibit increased expression of TGF-ß1 protein 
(Kim et al. 2002). 
Mesangial expression of TGF-ß isoforms is transiently upregulated in acute anti-Thy1.1 
nephritis, a rodent model of mesangial proliferative GN (Hartner et al. 2003; Ito et al. 2001; 
Liu et al. 2004), in which TGF-ß1 expression is only segmentally and weakly distributed (Ito 
et al. 2001).  
3.2 Primary FSGS 
Primary FSGS is a clinicopathologic entity characterized by nephrotic syndrome and 
progression to ESRD. Intrarenal transcription of TGF-ß1 is increased in children with FSGS 
compared to those with minimal lesion, suggesting that TGF-ß1 gene transcription is 
indicative of progressive renal damage typical of FSGS (Strehlau et al. 2002). Expression of 
TGF-ß1 is increased in patients with primary FSGS, particularly in podocytes of sclerotic 
segments (Kim et al. 2003). Volume density of mesangial matrix is significantly greater in 
the FSGS patients than in minimal lesion cases. In patients with FSGS, the percent 
glomerulosclerosis correlates directly with mesangial volume per glomerulus (Lee and Lim 
1995). 
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3.3 The significance of FSGS formation in chronic glomerular disease 
Some authors regarded FSGS as a nonspecific heterogeneous form of renal injury 
(Whitworth et al. 1978). The lesions of FSGS following primary glomerular diseases, such as 
IgAN and membranous nephropathy, have often been excluded in the category of 
secondary FSGS, because they were regarded as the nonspecific chronic scarred phase of the 
disease (D’Agati et al. 2004). Nonetheless, the lesions of FSGS in IgAN show 
immunohistochemical changes, which are basically identical to those described in primary 
FSGS, with loss of podocyte markers (Hill et al. 2011). Furthermore, podocytes covering the 
sclerotic segments exhibit enhanced expression of TGF-ß1 in IgAN and advanced diabetic 
nephropathy similar to those observed in primary FSGS. Thus, common podocyte lesions 
may contribute to the development of FSGS in both primary FSGS and other chronic 
glomerular diseases. 
3.4 Membranous nephropathy 
Membranous nephropathy is a well-characterized histological entity with a highly variable 
clinical course. Overall, approximately 30-40% of patients develop significant renal failure 
10-15 years after the diagnosis of nephropathy (Perna et al. 2004). New genomwide 
association study suggests that sequence variations within HLA and receptor for 
phospholipase A2 are responsible in part for the development of idiopathic membranous 
nephropathy (Stanescu et al. 2011). The hallmark of membranous nephropathy is the 
presence of glomerular subepithelial deposits that typically contain immunoglobulin and 
complement component. Between and around these deposits, the GBM is thickened due to 
the accumulation of GBM material, forming subepithelial projections or spikes. Complement 
membrane attack complex (C5b-C9) plays an important role in the development of podocyte 
injury and proteinuria in passive Heymann nephritis (PHN), an experimental model of 
human membranous nephropathy (Couser and Nangaku 2006). Upregulation of TGF-ß1 
and GBM protein mRNAs by podocytes is shown in patients with membranous 
nephropathy (Kim et al. 1999). Expression of TGF-ß2 is also markedly increased in 
podocytes in experimental membranous nephropathy, together with upregulation of TGF-ß 
receptors (Shankland et al. 1996). 
Lesions of FSGS are observed in 43% of the membranous nephropathty patients, in whom 
the degree of mesangial expansion and GBM thickening is significantly greater than the 
remaining cases without FSGS (Lee and Koh 1993). In PHN, mesangial volume was also 
significantly elevated, together with GBM thickening (Remuzzi et al. 1999). 
3.5 Diabetic nephropathy 
Diabetic nephropathy remains the most common cause for ESRD as the burden of 
diabetes increases worldwide. Nearly one-third of patients with diabetes develop 
nephropathy (Choudhury et al. 2010). Mesangial matrix expansion and thickening of the 
GBM are hallmarks of diabetic nephropathy, which occur even within a few years after 
the onset of type 1 diabetes (Drummond and Mauer 2002). If left untreated, 20-40% of 
patients with type 2 diabetes show progression to renal failure (Adler et al. 2003; Remuzzi 
et al. 2002).   
In the early stage of human diabetic nephropathy, some mesangial cells show 
immunoreactivity for TGF-ß1. Yet mesangial immunostaining for active TGF-ß1 is very 
weak or almost negligible in most human diabetic nodular glomerulosclerosis, despite 
increased mesangial TGF-ß1 mRNA levels. Rather, podocytes covering the sclerotic 
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segments show increased expression of TGF-ß1 mRNA and protein (Wahab et al. 2005). In 
the glomeruli of experimental diabetic nephropathy, only a few cells show positive 
immunostaining for TGF-ß1 (Hill et al. 2000). Enhanced expression of glomerular TGF-ß1 is 
observed mainly in podocytes of diabetic animals (Baba et al. 2005; Okada et al. 2006). 
3.6 Alport renal disease 
Collagen type IV is the main component of the GBM, which includes six genetically distinct 
isoforms named 1(IV) to 6(IV). The 3-5(IV) chains originate solely from podocytes in 
both the developing and mature glomerulus (Abrahamson et al. 2009). The 12(IV) 
collagen network, by contrast, seems to originate mainly from glomerular endothelial cells 
(Lee et al. 1993), and is localized predominantly at the endothelial aspect of human GBM 
(Zhang and Lee 1997).  
Alport syndrome is primary genetic disease of the basement membrane. In the kidney, this 
disorder is characterized by an absence of collagen 345(IV) in the GBM, progressive 
thickening and multilamination of the GBM, proteinuria, and renal failure. Yet collagen 
1/2(IV) is retained throughout the GBM (Abrahamson et al. 2003; Kashtan et al. 2001).  In 
podocytes of 3(IV) collagen-knockout mice with Alport renal disease, mRNA expression of 
TGF-ß1 is increased (Sayers et al. 1999).  With disease progression, mesangial matrix and 
cells are increased, followed by the development of glomerulosclerosis (Gregory et al. 1996; 
Kim et al. 1995). 
3.7 Denys-Drash syndrome  
Wilms’ tumour suppressor gene, WT1, is essential for normal podocyte function. Mutations of 
WT1 induce Denys-Drash syndrome (DDS) characterized by diffuse mesangial sclerosis. In 
DDS mice, the development of glomerulosclerosis is preceded by de novo TGF-ß1 expression 
in podocytes, while TGF-ß1 expression is absent in the mesangium (Patek et al. 2003).   
In summary, expression of TGF-ß1 by podocytes is increased not only in progressive podocyte disease 
but also in chronic mesangial disease. Despite mesangial matrix expansion in association with 
glomerulosclerosis in both types of disease, immunohistochemical antigen detection for mesangial 
TGF-ß1 seems to be difficult even in chronic mesangial disease.  
4. Activation of latent TGF-ß 
TGF-ß is secreted as latent complexes associated with a latency-associated peptide (LAP). 
TGF-ß/LAP complex is referred to as the small latent complex. Most cells secrete TGF-ß as 
part of a large latent complex, in which latent TGF-ß binding protein (LTBP) is linked to the 
small latent complex. LTBP has a role in targeting the transport of latent TGF-ß complex into 
the ECM (Hyytiäinen et al. 2004; Koli et al. 2008).  
The large latent complex is susceptible to proteolysis, within which LTBP is first cleaved at 
the protease sensitive hinge region. The soluble large latent complex is then released from 
the ECM and is activated by another proteolytic event that releases TGF-ß from LAP (Koli et 
al. 2001). The TGF-ß released then binds to its receptor and exerts its cellular functions. 
Under in vitro conditions, latent TGF-ß is activated by heating, acid or alkaline treatment, 
irradiation, reactive oxygen species (ROS), proteases including plasmin, cathepsin, calpain, 
matrix metalloproteinase (MMP)-2 and MMP-9, some integrins, or thrombospondin-1  
(TSP-1) (for review, see Koli et al. 2001).  
Several activation mechanisms may exist in vivo as reviewed below (Table 1). 
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4.1 TGF-ß activation by proteolysis 
Plasmin could function as an in vivo activator of TGF-ß (Lyons et al. 1990; Edgtton et al. 
2004). Plasmin can release the large latent TGF-ß complex from the ECM by cleaving LTBP 
at the amino terminal hinge region (Taipale et al. 1992). Furthermore, it can cleave LAP that 
releases active TGF-ß dimer from the large latent TGF-ß1 complex (Annes et al. 2003; George 
et al. 2005; Lyons et al. 1990). 
MMP-2 and MMP–9 have also been implicated in the cleavage of LAP and the release of 
mature TGF-ß at the cell surface (Yu and Stamenkovic 2000). 
4.2 TSP-1-mediated activation of TGF-ß 
TSP-1 is known to be a major physiologic activator of latent TGF-ß (Crawford et al. 1998). A 
specific peptide sequence within TSP-1, KRFK, binds to the LSKL sequence in LAP, and releases 
mature TGF-ß by inducing conformational changes in the protein (Crawford et al. 1998; 
Lawrence 2001; Koli et al. 2008). However, it is not clear whether TSP-1 alone could directly 
activate latent TGF-ß (Abdelouahed et al. 2000; Grainger and Frow 2000; Otsuka et al. 2007). 
Overexpression of both TSP-1 and active TGF-ß occurs in podocytes in patients with FSGS 
(Kim et al. 2003) and diabetic nephropathy (Wahab et al. 2005). In various experimental 
renal disease models, TSP-1 is co-localized with TGF-ß and predicts the development of 
tissue fibrosis (Hugo et al. 1998). 
4.3 ROS-mediated activation of TGF-ß 
ROS produced by ionizing radiation was found to induce rapid TGF-ß activation in vivo 
(Barcellos-Hoff and Dix 1996). ROS can activate TGF-ß directly through oxidation-induced 
conformational change in LAP, in which the unique methionine residue in the TGF-ß1/LAP 
functions as a redox switch center (Jobling et al. 2006), or indirectly through the activation of 
proteolytic enzymes (Koli et al. 2008). 
4.4 Integrins in TGF-ß binding and activation 
Integrins can bind to the RGD recognition domain in the LAP of TGF-ß1 and TGF-ß3. 
Particularly, αvß6 and αvß8 are known to activate the TGF-ß complex (Munger et al. 1999; 
Mu et al. 2002), leading to release of TGF-ß either by tractional force (αvß6) or by membrane 
type-1 MMP (MT1-MMP)-dependent proteolytic activity (αvß8) (Koli et al. 2008). By cell 
movement, an αvß6–integrin-expressing cell causes sufficient traction for the release of 
mature TGF-ß from the ECM-anchored large latent complex (Annes et al. 2004).  
 
Activators Mechanisms of action 1st author 
Plasmin 
- Proteolytic nicking of LTBP releasing large latent 
TGF-ß complex from the ECM 
- Proteolytic nicking of the LAP 
Taipale (1992); Lyons (1990); 
Annes (2003); George (2005) 
TSP-1 - Induction of conformational changes in LAP 
Crawford(1998); Lawrence 
(2001); Koli (2008) 
ROS 
- Induction of conformational changes in LAP
- Inducing activation of proteolytic enzymes 
Jobling (2006); Koli (2008) 
Integrin, αvß6 - Release of TGF-ß from LAP by tractional force Annes (2004) 
TGF-ß, transforming growth factor-ß; LTBP, latent TGF-ß binding protein; ECM, extracellular matrix; 
TSP-1, thrombospondin-1; LAP, latency-associated peptide; ROS, reactive oxygen species.  
Table 1. Proposed mechanisms for latent TGF-ß activation in chronic glomerular disease  
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αvß6 integrin is expressed in the diseased kidneys confined to the distal tubules and 
collecting ducts (Trevillian et al. 2004).  Deleting TGF-ß type II receptor in collecting duct 
cells in vitro resulted in increased integrin αvß6-dependent TGF-ß activation, that increased 
collagen synthesis in co-cultured renal interstitial fibroblasts (Gewin et al. 2010). 
5. Mechanism of TGF-ß overexpression by podocytes in chronic glomerular 
disease 
5.1 Incomplete activation of mesangial TGF-ß in chronic mesangial disease 
Intense mesangial immunostaining for LTBP-1 is observed in anti-Thy1.1 nephritis 
associated with severe but transient mesangial matrix accumulation (Porst et al. 2006). In 
rats with anti-Thy1.1 nephritis, active TGF-ß1-positive area/glomerulus was 18%, while 
treatment with antisense TSP-1 oligodeoxynucleotides reduced it to 9% (Daniel et al. 2003). 
In wild-type and TSP-1 deficient diabetic mice, the TGF-ß1-positive area in the glomerulus 
was 5% and 3%, respectively (Daniel et al. 2007). Thus, TSP-1 seems to activate mesangial 
TGF-ß1 more actively in acute mesangial proliferative GN than in chronic mesangial 
disease. 
Plasmin can release the large latent TGF-ß complex from the mesangial matrix by cleaving 
LTBP at the amino terminal hinge region (Taipale et al. 1992) (Fig. 1). The plasmin-mediated  
 
        Synthesis                                     
 
    Large latent TGF-ß complex 
Matrix  association 
Secretion 
Mesangial 
matrix  
Mesangial 
cell 
  
Release 
Soluble large latent TGF-ß complex 
Capillary lumen 
 
Fig. 1. Incomplete activation of mesangial TGF-ß in chronic mesangial disease. Upon 
fibrogenic stimuli, large latent TGF-ß complex in association with latent TGF-ß binding 
protein (LTBP) is synthesized and secreted from mesangial cells. It is then associated with 
mesangial matrix via N-terminus of LTBP. In protease-mediated activation of TGF-ß, LTBP 
is first cleaved at the protease sensitive amino terminal hinge region, and soluble large latent 
complex is released.  
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TGF-ß activation, however, may be neutralized via feedback inhibition, since TGF-ß-
induced production of plasminogen activator inhibitor-1 decreases the active plasmin 
formation in mesangial cells (Baricos et al. 2003). Furthermore, accumulation of mesangial 
matrix progressed in association with enhanced mesangial fibrin deposition in rats with 
anti-Thy 1.1 nephritis (Liu et al. 2004). Thus, the mesangial cell surface surrounded by an 
enlarged matrix may not express sufficient plasmin to further cleave LAP that liberates 
active TGF-ß dimer from the large latent TGF-ß1 complex. 
In view of the enhanced expression of TGF-ß1 in podocytes in human IgAN (Kim et al. 2002) 
and end-stage diabetic nephropathy (Wahab et al. 2005), podocytes seem to respond to 
paracrine TGF-ß coming from the mesangium.  Even though free active TGF-ß is liberated 
from the mesangium, it has a very short half-life in plasma (2-3 min) (Coffey et al. 1987), in 
contrast to the latent TGF-ß complex with a significantly longer half-life (>100 min) 
(Wakefield et al. 1990). Thus, soluble forms of large latent TGF-ß complex, rather than active 
TGF-ß, may be localized to the podocyte surface after its release from the mesangial matrix 
(Fig. 1 and 2). 
 
 
From mesangium            Biomechanical strain 
 
                                           Ang II (ROS) 
                         Latent TGF-ß         
                                                        plasmin, MMPs 
                                            TSP-1 
 
podocyte 
Active TGF-ß 
Signaling 
TGF-ß R’ 
CMD PPD 
 
Fig. 2. Hypothetical pathway for TGF-ß activation by podocytes in the diseased glomeruli. 
Soluble large latent TGF-ß complex coming from the mesangium in chronic mesangial 
disease (CMD) and biomechanical strain-induced TGF-ß in progressive podocyte disease 
(PPD) may be the source of latent TGF-ß complex in podocytes. It is then activated by 
angiotensin II (Ang II)/reactive oxygen species (ROS), plasmin, matrix metalloproteinases 
(MMPs) and thrombospondin-1 (TSP-1). Active TGF-ß, which is released from latency-
associated peptide, is able to associate with the signaling receptors (TGF-ß R’), and signal 
transduction pathway is activated. 
5.2 Induction of podocyte TGF-ß by glomerular hypertension or biomechanical strain 
in progressive podocyte disease 
In progressive podocyte diseases, TGF-ß expression is increased in podocytes (Kim et al. 
1999, 2003; Patek et al. 2003; Sayers et al. 1999; Shankland et al. 1996; Wahab et al. 2005). 
Unlike mesangial cells, podocytes do not overexpress TGF-ß1 in response to common in 
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vitro metabolic stimuli, such as high glucose (Iglesias-de la Cruz et al. 2002) and angiotensin 
II (Ang II) (Chen et al. 2005). Yet albumin load or mechanical strain increases the levels of 
TGF-ß1 and Ang II, as well as TGF-ß type I, II and III receptors in cultured podocytes 
(Abbatte et al. 2002; Dessapt et al. 2009; Durvasula et al. 2004).  
Increased intraglomerular pressure results in cellular strain and perpetuates further damage 
to the podocytes in progressive glomerular disease, eventually leading to glomerulosclerosis 
(Kriz et al. 1998). The less cross-linked and possibly more elastic physical properties of the 
GBM in some podocyte diseases may subject the podocytes to elevated biomechanical strain 
even under normal glomerular blood pressure. As the disease progresses and nephron mass 
is lost, glomerular hypertension develops, further exacerbating the biomechanical strain and 
the effector functions influenced by it (Meehan et al. 2009). In the remnant kidney model of 
glomerular capillary hypertension, TGF-ß1 (Abbate et al. 2002) and Ang II type I receptor 
(Durvasula et al. 2004) are upregulated by podocytes.  
Together, an increase in glomerular capillary pressure may stimulate Ang II and TGF-ß1 
expression in podocytes through mechanical force injury in progressive podocyte diseases 
(Lee 2011) (Fig. 2). 
5.3 Activation of latent TGF-ß by podocytes in chronic glomerular disease 
In podocyte diseases, Ang II-induced oxidative stress may activate the latent TGF-ß and, 
subsequently, the TGF-ß signaling system in podocytes (Lee 2011) (Fig. 2). Indeed, diabetic 
podocytopathy seems to be mediated by Ang II (Ziyadeh and Wolf 2008) and oxidative 
damage (Zheng et al. 2008).  
Osteopontin expression strongly correlates with glomerular disease, and is increased 
specifically in podocytes. Treatment of podocytes with recombinant osteopontin activated 
the NF-κB pathway, increased the expression of urokinase-type plasminogen activator 
(uPA) and MMP-2 and -9, and increased podocyte motility (Lorenzen et al. 2008). Strong 
expression of uPA protein and mRNA is sometimes observed within crescents (Lee et al. 
2001). These observations suggest that damaged podocytes in the diseased glomeruli may 
release plasmin, MMP-2 and -9 to activate latent TGF-ß (Fig. 2). 
In human FSGS, expression levels of TGF-ß1, TSP-1 and TGF-ß type II receptor mRNAs and 
proteins as with phosphorylated Smad2/Smad3 are increased by podocytes (Kim et al. 
2003), suggesting that TSP-1 may activate TGF-ß in podocytes (Fig. 2). In addition, diabetic 
mediators upregulate the TGF-ß type II receptor that both binds the ligand and initiates the 
signaling cascade, suggesting that the podocyte is primed to respond to TGF-ß (Iglesias-de 
la Cruz et al. 2002; Wolf et al. 2005). 
Altogether, podocyte-derived plasmin, MMPs and TSP-1, and particularly Ang II-induced 
oxidative stress may activate the latent TGF-ß in podocytes in diseased glomeruli. The 
activated TGF-ß may bind to its receptor on podocytes, activating the TGF-ß/Smad 
signaling pathway to induce the expression of its target genes, such as connective tissue 
growth factor (CTGF) and vascular endothelial growth factor (VEGF) (Fig. 2 and 3). 
6. Paracrine effector mechanism of CTGF and VEGF for TGF-ß to act on 
mesangial cells  
The podocyte TGF-ß, the active form of which has a very short half-life in plasma, is 
unlikely to traverse the GBM to promote sclerosis in the adjacent mesangium. Instead, some 
TGF-ß-induced humoral factors produced by podocytes seem to have fibrogenic effects on 
mesangial cells (Lee and Song 2009b). 
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CTGF is a major autocrine growth factor induced by TGF-ß. TGF-ß1 induces CTGF mRNA 
and protein expression in podocytes (Ito et al. 2001) and mesangial cells (Riser et al. 2000). 
Expression of CTGF mRNA and/or protein in the mesangium and podocytes is upregulated 
in human chronic glomerular disease (Ito et al. 1998; Wahab et al. 2005). It is increased 
particularly in the glomeruli of patients with mesangial matrix expansion (Suzuki et al. 2003). 
Treatment with the CTGF antisense oligonucleotides significantly reduced the mesangial 
matrix expansion in diabetic mice (Guha et al. 2007). Furthermore, induction of diabetes in 
podocyte-specific CTGF-transgenic mice results in an increased mesangial CTGF expression 
with more severe mesangial expansion than diabetic wild-type mice (Yokoi et al. 2008).  
TGF-ß1 stimulates VEGF expression in podocytes (Iglesias-de la Cruz et al. 2002). VEGF is a 
potent angiogenic molecule and is detected predominantly in podocytes (Bailey et al. 1999; 
Wendt et al. 2003). Yet glomeruli are not sites of angiogenesis, possibly because podocytes 
mainly express VEGF165b protein, which inhibits VEGF165-mediated angiogenesis (Cui et al. 
2004). VEGF may play an important role in TGF-ß1-induced glomerular fibrosis (Chen et al. 
2004, 2005). VEGF overexpression by podocytes led to mesangial expansion (Veron et al. 
2010; Zhang et al. 2010). Furthermore, anti-VEGF attenuates the mesangial matrix expansion 
in diabetic mice (Flyvbjerg et al. 2002).  
The dominant production of VEGF-A by podocytes and the localization of its receptor, 
VEGFR-2, on glomerular endothelial cells suggest that VEGF-A moves across the GBM, 
opposing the ultrafiltration gradient to move water and solutes from the capillaries into the 
Bowman’s space (Satchell et al. 2006). In fact, about one third of VEGF secreted from  
 
 
 
Podocyte 
CTGF, VEGF 
TGF-ß R’ 
Active TGF-ß 
Smads 
Mesangial cell 
Capillary lumen 
Mesangial      
matrix Glomerulosclerosis 
 
Fig. 3. Hypothetical pathway for mesangial matrix accumulation via activation of TGF-ß by 
podocytes in chronic glomerular disease. The activated TGF-ß may bind to its receptor 
(TGF-ß R’) on podocytes, activating TGF-ß/Smad signaling pathway to induce the 
overexpression of its target genes, connective tissue growth factor (CTGF) and vascular 
endothelial growth factor (VEGF). The CTGF and VEGF secreted from podocytes may reach 
the capillary lumen and stimulate mesagial cells to produce excessive matrix proteins, 
culminating in the development of glomerulosclerosis. 
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podocytes would reach the capillary lumen and accumulate there, supporting the view that 
VEGF can move against the flow of glomerular filtration (Katavetin and Katavetin 2008). 
Although it is not clear whether this is also the case for CTGF, the experiments performed 
by Yokoi et al. (2008) support that possibility. 
 In summary, TGF-ß-induced CTGF and VEGF secretion by podocytes may act as an effector 
mechanism, necessary for mesangial matrix accumulation in chronic glomerular disease, 
culminating in the development of glomerulosclerosis (Fig. 3). 
7. Conclusions 
In chronic mesangial disease, large latent TGF-ß complexes secreted by mesangial cells may 
be stored in the mesangial matrix, from which soluble large latent TGF-ß complexes may be 
released and localized to the podocyte surface. In progressive podocyte disease, by contrast, 
mechanical pressure or biomechanical strain may upregulate Ang II and TGF-ß expression 
in podocytes. In both chronic mesangial disease and progressive podocyte disease, 
podocyte-derived plasmin, TSP-1 and ROS, particularly Ang II-induced oxidative stress, 
seem to be involved in TGF-ß activation. Active TGF-ß may induce CTGF and VEGF 
overexpression in podocytes, which may act as a paracrine effector mechanism on 
mesangial cells to stimulate mesangial matrix synthesis culminating in the development of 
glomerulosclerosis. In summary, this review provides new mechanistic insights into the role 
of TGF-ß in mesangial matrix synthesis in chronic progressive glomerular disease. Better 
understanding of the activation of TGF-ß signaling and its downstream effectors, CTGF and 
VEGF, may provide novel tools for the prevention of glomerulosclerosis. 
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